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Abstract
High flow nasal cannula (HFNC) is a relatively new non-invasive ventilation therapy that seems to be well tolerated
in children. Recently a marked increase in the use of HFNC has been seen both in paediatric and adult care
settings. The aim of this study was to review the current knowledge of HFNC regarding mechanisms of action,
safety, clinical effects and tolerance in children beyond the newborn period.
We performed a systematic search of the databases PubMed, Medline, EMBASE and Cochrane up to 12th of May
2016. Twenty-six clinical studies including children on HFNC beyond the newborn period with various respiratory
diseases hospitalised in an emergency department, paediatric intensive care unit or general ward were included.
Five of these studies were interventional studies and 21 were observational studies. Thirteen studies included only
children with bronchiolitis, while the other studies included children with various respiratory conditions. Studies
including infants hospitalised in a neonatal ward, or adults over 18 years of age, as well as expert reviews, were not
systematically evaluated, but discussed if appropriate.
The available studies suggest that HFNC is a relatively safe, well-tolerated and feasible method for delivering
oxygen to children with few adverse events having been reported. Different mechanisms including washout of
nasopharyngeal dead space, increased pulmonary compliance and some degree of distending airway pressure may
be responsible for the effect. A positive clinical effect on various respiratory parameters has been observed and
studies suggest that HFNC may reduce the work of breathing. Studies including children beyond the newborn
period have found that HFNC may reduce the need of continuous positive airway pressure (CPAP) and invasive
ventilation, but these studies are observational and have a low level of evidence. There are no international
guidelines regarding flow rates and the optimal maximal flow for HFNC is not known, but few studies have used a
flow rate higher than 10 L/min for infants.
Until more evidence from randomized studies is available, HFNC may be used as a supplementary form of
respiratory support in children, but with a critical approach regarding effect and safety, particularly when operated
outside of a paediatric intensive care unit.
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Background
High flow nasal cannula (HFNC) oxygen delivery, also
sometimes called heated humidified high flow nasal can-
nula (HHHFNC), is a relatively new non-invasive venti-
lation therapy that seems to be well tolerated in
neonates and adults with hypoxemic respiratory failure
[1–3]. Before the introduction of HFNC, traditionally a
maximum flow of 0.5–1 L/min for delivery of oxygen by
nasal cannula was set in newborns [4, 5] and a max-
imum flow of 2 L/min was used for older children and
adults in order to prevent drying and discomfort of the
nasal mucosa and other nasal mucosal complications [6].
High flow is usually defined as flow rate ≥2 L/min, the
flow rate depending on the type of cannula used, but
ranging from 4 to 70 L/min [7]. Debate is ongoing as to
whether HFNC may reduce the use of less tolerated and
more invasive ventilator supports, such as continuous
positive airway pressure (CPAP) and mechanical
ventilation.
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HFNC was first introduced to treat preterm infants as
an alternative to CPAP [5], but recently a marked in-
crease in the use of HFNC has been seen both in paedi-
atric and adult care settings [7–11]. In children, its use
has particularly proliferated for infants and young chil-
dren hospitalised with bronchiolitis. However, the evi-
dence for the safety or effectiveness of HFNC as a
respiratory support in children is relatively lacking, as
underlined in two Cochrane reviews from 2014 [7, 12].
Despite that, HFNC has been increasingly implemented
in clinical practice, and given that modification, it is es-
sential that physicians should keep abreast of the latest
knowledge. The aim of this study was to review the
current evidence of HFNC regarding mechanisms of ac-
tion, safety, clinical effects and tolerance in children be-
yond the newborn period.
Methods - literature search
We performed a systematic literature search of the data-
bases PubMed, Medline, EMBASE and Cochrane up to
12th of May 2016. We first searched for all articles with
the keywords high flow nasal cannula or HFNC and lim-
ited the search to articles in English or a Scandinavian
language and articles including children 0–18 years of
age. The further inclusion criteria were: Studies includ-
ing children with various respiratory diseases treated
with HFNC hospitalised in an emergency department,
paediatric intensive care unit or general paediatric ward
studying mechanism of action, pressure, flow rate, clin-
ical effect (ventilation, admission to paediatric intensive
care unit, length of stay), patient comfort, safety and
studies comparing HFNC to CPAP. All original clinical
studies, both interventional randomized controlled stud-
ies and observational retrospective and prospective stud-
ies including children on HFNC beyond the newborn
period were included and evaluated, but individual stud-
ies were not systematically assessed for the risk of bias.
Details regarding study design, flow rate, outcome and
key results of these studies were summarized.
From the original search, we excluded studies that did
not meet the inclusion criteria in a hierarchical manner
according to the following criteria.
1. Studies including only infants hospitalized in a
neonatal care unit
2. Studies not corresponding to the inclusion criteria
3. Not a clinical trial
4. Studies including only adults >18 years of age
First the title of a study, as it appeared from the search
was read and searched for the exclusion criteria de-
scribed above. If a study could not be excluded based on
the title, the abstract was read. Based on the abstract, we
excluded studies that did not meet the inclusion criteria.
If exclusion could not be done based on the abstract, the
entire article was read.
Studies including infants hospitalised in a neonatal
ward or adults over 18 years of age, as well as expert re-
views and Cochrane reviews, were not evaluated, but
were discussed if appropriate (Fig. 1).
Definition of HFNC
In the Cochrane review from 2014, HHHFNC in chil-
dren was defined as heated, humidified and blended
air/oxygen delivered via nasal cannula at different
flow rates ≥ 2 L/min, delivering both high concentra-
tions of oxygen and potentially continuous distending
pressure [7].
Description of clinical studies on HFNC
Twenty-six clinical studies including children on HFNC
beyond the newborn period were found (Fig. 2). An
overview of the study design, outcome and key results of
the included studies is given in Table 1.
Thirteen studies included only children hospitalized
with bronchiolitis, ten studies included children hospi-
talized with respiratory distress due to various airway
disorders, one study included paediatric cardiac surgical
patients and two studies included children with ob-
structive apnoea-hypopnea syndrome. The bronchiolitis
studies included children up to 24 months of age, while
the other studies included children up to 18 years of age.
Overall, the majority of children studied were below 2
years of age. Six of the bronchiolitis studies included
children in a paediatric intensive care unit (PICU), five
included children hospitalised in general paediatric
wards and two studies included children in emergency
departments. HFNC devices with flow rates ranging
from 4–10 L/min were used for children younger than
24 months of age [13–24], and flows of up to 50 L/min
were used in older children [25–29].
Six studies estimated distending airway pressure [13,
14, 17, 23, 26, 30], eight evaluated feasibility and safety
[16, 18, 24, 26, 27, 31–33], while five studies attempted
to predict non-responders to HFNC therapy [16, 19, 32,
34, 35]. Nine studies evaluated the clinical effects mea-
sured by respiratory rate, heart rate, blood gas values,
SpO2 (peripheral capillary oxygen saturation), FiO2
(fraction of inspired oxygen) and length of stay (LOS)
[21, 23, 24, 26, 28, 31–33, 36], while five studies had in-
tubation as an outcome [15, 21, 29, 32, 37]. One study
compared HFNC to inhalation of hypertonic saline [20]
and two studies compared HFNC to CPAP [22, 27].
Mechanisms of action of HFNC
The suggested mechanisms of actions of HFNC are:
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1) Washout of nasopharyngeal dead space resulting in
increased fraction of oxygen and carbon dioxide in
the alveoli [38, 39],
2) Reduction of inspiratory resistance and work of
breathing by providing adequate flow [30, 39],
3) Improvement of airway conductance and pulmonary
compliance by reducing the effect of cold air; an in
vitro study has shown that inspired gas with low
humidity even for short periods may result in
worsened function of human airway epithelial cells
inflammatory indices [39, 40],
4) Reduction of the metabolic cost of gas conditions by
providing air with 100 % relative humidity [39],
5) Providing an end-distending pressure to the lungs
[13, 17, 30, 38, 39].
Pressure generated by HFNC
The pressure delivered to the distal airway is difficult to
measure. Various indirect methods are used, i.e. pressure
in oesophagus [23, 30], pharynx [13], nasopharynx [14,
26, 41], electrical impedance tomography on the surface
of the chest [17] or electrical activity of the diaphragm
[30]. One of the first studies published on HFNC in neo-
nates showed that a flow of 2 L/min could generate a
high oesophageal pressure of up to 9.8 cm H2O [42]. Re-
cent studies have suggested limited pressure delivery as
measured in pharynx and oesophagus, ranging from 2–
4 cm H2O both in children [13, 14, 26] and adults [41].
A prospective study including 25 patients below 18 years
of age, found higher pleural pressure on HFNC with
flows of 8 L/min compared to flows of 2 L/min [23].
Fig. 1 Flow diagram of the search history and the numbers of excluded and included studies
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Similarly in a lung model study, the positive distending
pressure to the lungs increased as the flow increased
from 0 L/min to 12 L/min [43]. Overall, the distending
airway pressure appears to be dependent on the weight/
size of the patient, flow rate, and the diameter of the
nasal cannula compared to the nares, with a higher pres-
sure being delivered when the mouth is closed [14, 42,
44, 45]. In conventional nasal CPAP, the pressure that
the patient breathes is controlled via a valve providing
an escape route. In HFNC there is no equivalent control
valve, and the only escape routes are the leak at the
nares-prong interface and via the mouth [43, 44].
Level of flow
The optimal maximal flow for HFNC is not known.
In most studies included in this paper, the flow rate
used varied from 2 to 8 L/min and was adjusted indi-
vidually to minimize the patients’ work of breathing
and SpO2 values. In nine studies, the flow rate was
estimated by the patient’s weight [16, 22, 27, 28, 30,
32, 33, 35, 37]. Six of these studies used a flow of
2 L/kg/min, with a maximum flow of 8–12 L/min be-
ing used in two studies (Table 1). One study reported
a flow rate varying from 1 to 3 L/kg/min, but a max
flow of 8 L/min [22]. In a study including children
hospitalized with bronchiolitis in a general paediatric
ward, a flow of 2 L/kg/min, with a max flow of 10 L/
min was safe with no adverse events [16].
In a recently published review from Hutchings et al., a
guideline for the initiation and strategies for escalation
and weaning of HFNC in a general paediatric ward was
suggested [46]. In this local guideline, the initial flow is
set dependent on age, and the flow is increased if the
points in a particular patient scoring system are above a
given trigger level. The authors discuss the alternative of
using flow rates per kg, but underline that such an ap-
proach might result in very high flow rates.
As shown in the present paper, few studies including
infants have used a flow rate above 10 L/min, and there
are no studies comparing flow rates above 10 L/min and
pressure. Higher flow rates up to 50 L/min have been
used in studies including older children and adults [26,
29, 47]. Flow rates up to 1.5-2 L/kg/min are being used
in children both in general paediatric wards and PICUs
(Table 1). However, the lack of studies using higher flow
rates and the few case reports of serious air leakage in
children treated with HFNC [48] indicate that caution
should be exercised with increasing flow rates higher
than 1 L/kg/min in children or higher than 10 L/min for
infants, particularly outside of a PICU.
Clinical effects
Ventilation and oxygenation
In a prospective randomized open pilot study including
19 infants hospitalised with bronchiolitis, a higher me-
dian SpO2 at 8 and 12 h, but not at 24 h, was found in
the HFNC group than in a group receiving head-box
oxygen [24]. In a RCT of children undergoing cardiac
surgery, improvement of partial pressure of oxygen/frac-
tion of inspired oxygen (PaO2/FiO2) was found after
extubation in children receiving HFNC compared to
oxygen given by cannulas with a maximum flow rate of
2 L/min [28]. A reduction in respiratory rate and im-
provement of blood gas parameters has also been re-
ported in other prospective bronchiolitis studies, details
are given in Table 1 [18, 21, 26, 31, 33].
Admission to PICU and length of stay
The only case control study on the effect of HFNC on
admission to PICU found that admission was four times
less likely in children receiving HFNC than children re-
ceiving standard treatment [16]. However, there was no
difference in the length of stay (LOS). One small pro-
spective observational study including children with
bronchiolitis found that LOS was 3 days shorter in chil-
dren receiving HFNC than children receiving low flow
oxygen [33]. Another retrospective bronchiolitis study
found that the median hospital LOS was 4 days vs. 3 days
before and after the introduction of HFNC in the gen-
eral wards [36]. However, no differences in LOS were
Fig. 2 Overview of the study design of the clinical studies included in the present paper
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Study design Study group
Number of participants
Age
Flow rate Main outcomes Key results






27 infants with bronchiolitis in a
general paediatric ward.
Age <12 months.
Max 8 L/min. Clinical parameters (end tidal Co2, respiratory
rate, heart rate, SpO2).
Feasibility of HFNC (adverse events).
Decrease in median end tidal CO2 (6–8 mmHg) and
respiratory rate (13–20 per minute) in the first 3 h of















Pressure in nasopharynx at varying flow rates of
HFNC.
Increasing flow rates of HFNC up to 6 L/min were







45 infants with bronchiolitis in a
general paediatric ward.
Age <15 months.
Not given. Clinical parameters (heart rate, respiratory rate,
blood gas parameters).
Adverse events.
Decrease of heart rate (median 171 to 136) and
respiratory rate (median 79 to 53) and improvement in
Ph (median 7.32 to 7.38) and PaCO2 (median 7.7 to 6.6









19 infants with bronchiolitis in a
general paediatric ward.
Infants were randomized to
head-box oxygen (n = 8) or HFNC
(n = 11).
Age <12 months.
4-8 L/min. Safety and feasibility of HFNC in infants with
bronchiolitis.
SpO2 8 h after randomization and other clinical
parameters at intervals up to 48 h.
Median SpO2 was higher in the HFNC group at 8 and
12 h, but similar at 24 h.












61 infants with bronchiolitis
treated with HFNC in a general
paediatric ward.
33 infants with bronchiolitis





Clinical data (heart rate, respiratory rate, SpO2,
LOS) admission to PICU and adverse events
Nonresponders to HFNC can be identified early.
Four times higher risk of admission to PICU in the
standard treatment group than in the HFNC group.









75 infants with bronchiolitis in
general paediatric ward.




Max 8 L/min. Respiratory distress (measured by scoring
system), patient comfort, LOS, admission to
PICU in the two groups.
HFNC was not superior to hypertonic saline in
treatment of moderate acute bronchiolitis with respect






36 children hospitalised with
bronchiolitis in an emergency
department.
18 treated with HFNC,
18 with low-flow oxygen.
Age < 12 months.
8 L/kg * respiratory
rate *0.3.
Respiratory rate, respiratory effort, ability to feed
and LOS in the two groups.
Improvements in respiratory rate, respiratory effort and
ability to feed were faster in the HFNC group.
The HFNC group needed oxygen for 2 days less and
LOS was 3 days shorter than in the low flow oxygen
group.

























Table 1 Overview of the 26 original clinical studies including children on HFNC beyond the newborn period (Continued)
[19] Age ≤12 months. Characteristics of non-responders to HFNC mea-
sured by respiratory rate, blood gas parameters
and SaO2.
Nonresponders were more hypercarbic, less tachypnic







21 infants with RSV bronchiolitis
in PICU.
Age <6 months.
1-7 L/min. Pharyngeal pressure provided by HFCNC using
flow rates from 1–7 L/min and the effect of
HFNC on breathing pattern and respiratory
effort.
HFNC with a flow rate equal to or above 2 L/kg/min
generated a clinically relevant pharyngeal pressure






13 infants with bronchiolitis in
PICU.
Age <12 months.
2 and 8 L/min.
Average rate 1.7 L/
kg/min.
End-expiratory lung volume, continuous
distending pressure and regional ventilation
distribution by measuring electrical impedance
tomography.
HFNC at 8 L/min increased end-expiratory lung volume
and improved respiratory rate, FiO2 and SpO2 com-








115 infants with bronchiolitis
admitted to PICU during two
seasons.
57 children before introduction
of HFNC and 58 children after
implementation of HFNC.
Age <24 months.
7-8 L/min. Intubation rate in PICU after introduction of
HFNC.
Clinical parameters (respiratory rate, LOS).
Intubation rate decreased from 23 % (2005–2006) to
9 % (2006–2007) after introduction of HFNC in the
department.
After 1 h on HFNC, respiratory rate decreased (−12
breaths/min) in infants treated with HFNC.







34 children with bronchiolitis in
PICU.
19 children on CPAP (first





LOS and other clinical parameters in children
on CPAP and HFNC during two seasons.
No difference between the groups in length of stay,






120 infants admitted with
bronchiolitis to PICU before and
170 after introduction of HFNC in
a general paediatric ward.







LOS, intubation rates, 30 days readmission and
median hospital charges.
LOS in PICU was reduced from 4–3 days, no difference
in intubation rate or readmission, the median total
hospital charges was reduced.







14 infants with bronchiolitis.




2 L/kg/min. Diaphragmatic electrical activity and
oesophageal pressure changes as a surrogate
for work of breath in infants off then on HFNC.
The electrical activity of the diaphragm and the
oesophageal pressure-swings in infants with bronchio-
litis were reduced.
A similar, but less prominent offload of the diaphragm







298 infants admitted to PICU,
56 % had bronchiolitis.
Age <24 months.
8 L/min at initiation. Ventilator practice in the 5-year period after the
introduction of HFNC therapy.
Intubation rate.
Intubation rate decreased from 37 % in 2005 to 7 % in
2009 in infants with bronchiolitis corresponding with







848 patients divided in 3 cohorts
admitted to PICU with acute
respiratory insufficiency.
24 % had bronchiolitis.
Cohort 1 (n = 190): HFNC not
available
Cohort 2 (n = 289): HFNC
available, but no guidelines.
Range 2–50 L/min.
Details not given.
The need of intubation and mechanical
ventilation before and after the availability of
HFNC.
Intubation rate decreased from 16 to 8 % after the
implementation of HFNC in PICU.



















Table 1 Overview of the 26 original clinical studies including children on HFNC beyond the newborn period (Continued)









25 patients in ICU receiving
HFNC or planned to be
extubated to HFNC.
Age < 18 years.
2-8 L/min. Effort of breathing in children on CPAP and
HFNC at different flow rates by measuring the
pressure-rate product (change in pleural pres-
sure multiplied by respiratory rate).
Oesophageal pressure was used as a surrogate
for pleural pressure.
Increasing flow rates (2, 5 and 8 L/min) of HFNC







109 children in PICU requiring
respiratory support for various
disease categories;
72 children on HFNC and 37 on
CPAP.
HFNC: median age 6 months,
CPAP: median age 5 months.
2 L/kg/min. Level of and duration of respiratory support,
and other clinical data in children on HFNC and
CPAP.
No significant difference in the number of children
requiring a higher level of respiratory support in the
two groups. ¼ of all children on HFNC required higher
level of respiratory support, these had failure of
normalization of heart rate and respiratory rate and not








89 paediatric cardiac surgical
patients in PICU.
Infants were randomized to
conventional O2 therapy (n = 46)
or HFNC (n = 43).
Age <18 months.
2 L/kg/min. Clinical characteristics and need for higher
respiratory support and reintubation rate.
48 h observational time.
PaCo2 did not differ between the group with HFNC
and conventional O2 therapy.
PaO2 was higher in the HFNC group.






46 neonates and children treated
for respiratory distress in PICU.
Patients were switched from
traditional oxygen therapy to
HFNC.
Age 0–12 years.
8-12 L/min in infants.
20–30 L/min in
children.
Tolerability and effectiveness of HFNC
treatment using COMFORT scale and
nasopharyngeal pressure.
COMFORT score and oxygen saturation improved in
children after switching to HFNC.
HFNC generated a positive end expiratory pressure of
4 ± 1.99 cm H2O; the pressure was dependent of






498 children admitted to
paediatric emergency
department with respiratory
distress, 46 % had bronchiolitis.
Age < 2 years.
Not given. Clinical and patient characteristics that predicts
success or failure of HFNC therapy.
Respiratory rate > 90th percentile for age, initial venous
PaCO2 > 50 mmHg, and initial venous pH < 7.30 were
associated with failure of HFNC therapy.
A diagnosis of acute bronchiolitis was protective with






54 children hospitalized in PICU
for various respiratory disorders.
79 % with bronchiolitis.
Median age 3.5 months.
2 L/kg/min. Failure of HFNC therapy defined as the patient
needing escalation of treatment to CPAP or
intubation.
HFNC was successful in 78 % of patients and failed for
12 patients (7 needed CPAP and 5 were intubated).
The failure rate was 50 % in children with a primary





71 children hospitalized with
various respiratory distress in
emergency department.
Median age 9 months.
2 L/kg/min up to
10 kg, 0.5 L/kg/min
thereafter.
Failure rate, predictors of failure and adverse
events.
28 (39 %) children required escalation to a higher level
of respiratory support. No serious adverse events in
emergency department, but one child developed air





Children with severe pneumonia;
randomised to CPAP, HFNC, or
low-flow oxygen.
<5 years of age.
2 L/kg/min, max
12 L/min.
Treatment failure after 1 h. Oxygen therapy delivered by CPAP improved
outcomes compared to low flow-oxygen, no difference
between HFNC and CPAP group.
























12 children with obstructive
apnoea-hypopnea syndrome in a
paediatric sleep disorder centre.
10 patients had undergone CPAP
titration before study start.
Age 10 ± 1 year.
20 L/min. Numbers of obstructive sleep apnoea, clinical
parameters (respiratory rate, arousals).
HFNC reduced the inspiratory flow limitation and
decreased respiratory rate.
HFNC decreased arousals and apnoea hypopnoea





5 children with obstructive sleep
apnoea not tolerating CPAP.
Age < 18 years.
≤10 L/min. Change in apnoea-hypopnoea index and oxy-
gen saturation.
Treatment with HFNC improved the apnoea-
hypopnoea index and increased oxygen saturation.
PICU pediatrics intensive care unit, HFNC high flow nasal cannula, FiO2 fraction of inspired oxygen, SpO2 peripheral capillary oxygen saturation, PaCo2 partial pressure of carbon dioxide, PaO2 partial pressure of


















found in a study comparing children with bronchiolitis
treated with HFNC and hypertonic saline [20], or in a
bronchiolitis study comparing children on CPAP and
HFNC during two seasons [22]. Similarly there were no
differences in LOS in an RCT comparing children under-
going cardiac surgery with conventional oxygen therapy
and HFNC [28], or in a retrospective observational case
control including children aged 0–18 years admitted to
PICU with acute respiratory insufficiency due to various
respiratory diseases [29]. The median LOS in PICU was
reduced from six to four hours in children hospitalised
with bronchiolitis treated with HFNC compared to chil-
dren hospitalized in seasons before the introduction of
HFNC [21], but this finding probably has limited clinical
importance, given the very short LOS reported.
In summary, studies on the effect of HFNC have iden-
tified a positive clinical effect on SpO2, PaO2, respira-
tory rate and blood gas parameters in some children,
especially for children with bronchiolitis. In children
with bronchiolitis, also some effect of HFNC has been
found on LOS and admission to PICU, but not in chil-
dren with other respiratory diseases.
Patient comfort with high flow
Only one small study in children outside the neonatal
period has studied patient tolerance and compliance.
This study included 46 children with various causes of
respiratory distresses from 0 to 12 years of age, and
found that patient comfort measured by COMFORT
scale improved when switching from oxygen delivered
by nasal cannula or face mask to HFNC [26]. In a small
study including 20 adults, high flow was reported to be
more comfortable and associated with less dyspnoea and
mouth dryness compared to oxygen delivered via face
mask [3]. In a Norwegian study among newborns, no
difference was found in patient comfort on HFNC and
CPAP, but parents preferred HFNC to CPAP, reporting
that their child was more satisfied, and that they per-
ceived that it was easier to interact with their child when
they were on HFNC [1]. However, a study on preterm
infants found no difference in noise levels between
CPAP and HFNC [2]. The results of these studies in ne-
onates may also be valid for young infants hospitalised
with bronchiolitis.
A survey from Australia and New Zealand directed at
senior medical and nursing staff noted that, despite a
lack of guidelines, HFNC was perceived as easy to ad-
minister and comfortable for infants [11]. It would seem
that this assessment of improved patient tolerance when
using HFNC compared to other forms of respiratory
support may also help explain its popularity with clinical
staff, and would appear to be one of the reasons for its
increasing use over recent years, despite a lack of evi-
dence for its clinical effectiveness.
Identification of non-responders
One study including children hospitalised with bronchio-
litis, identified responders and non-responders to HFNC
within 60 min of treatment; responders had lower heart
and respiratory rates, whereas no equivalent changes were
found among non-responders [16]. Similarly, early identi-
fication of non-responders was found in children on
HFNC hospitalised in a PICU for various causes of re-
spiratory distress, with a median increase in respiratory
rate at 1 h in the HFNC failure group [32]. Another study
also looking at young children with bronchiolitis con-
cluded that non-responders had no improvement in their
respiratory rate after the initiation of HFNC, were more
hypercarbic but also had a lower respiratory rate prior to
the start of HFNC, suggesting that perhaps they were
already tiring [19]. In a study of children under 2 years of
age presenting to an emergency department with respira-
tory distress, non-responders had a respiratory rate above
the 90th percentile for age, an initial venous partial pres-
sure of carbon dioxide (PaCO2) above 50 mmHg (6.7
kPa), and an initial venous pH less than 7.30 [34]. Meas-
urement of a blood gas and the recognition of hypercar-
bia, respiratory acidosis and tachypnea, may allow for
early identification of infants and children at increased risk
of not responding to HFNC, and therefor may be in need
of additional respiratory support.
High flow nasal cannula compared to CPAP
There is only one randomized controlled trial comparing
CPAP and HNFC in children after the newborn period
[37]. This study of children with severe pneumonia in
Bangladesh, found that when CPAP was compared to low
flow oxygen it improved outcome (intubation, death, clin-
ical failure), but found no difference in outcome between
children supported by HFNC or CPAP. A small retrospect-
ive study comparing children on HFNC and CPAP during
two seasons, found no difference between the groups re-
garding length of stay, respiratory rate, PaCO2, FiO2 or
duration of oxygen supply [22]. Similarly, another prospect-
ive study found no significant difference between children
on HFNC and CPAP regarding respiratory rate, heart rate,
arterial oxygen saturation (SaO2) or respiratory distress. In
this study, 26 % of the children on HFNC required an escal-
ation of respiratory support compared to 18 % in the CPAP
group (p = 0.27) [27].
An observational study investigating the pressure de-
livery system in vitro and in vivo on newborns, found
similar end-expiratory oesophagus pressures for neo-
nates treated with HFNC and CPAP [49]. In neonates
and adults, randomized controlled trials have shown no
different effects of CPAP and HFNC regarding intub-
ation. In preterm babies three randomized controlled
non-inferiority trials found similar effects of HFNC com-
pared to CPAP after extubation [50–52].
Mikalsen et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2016) 24:93 Page 9 of 12
Intubation
Five retrospective observational studies have assessed
the use of HFNC and the risk for intubation in children
[15, 21, 29, 32, 36]. Three of these studies concluded
that the use of HFNC was associated with an overall re-
duction in the intubation rates, however these studies
had a low level of evidence [15, 21, 29]. Two of the stud-
ies on children with bronchiolitis below 24 months of
age, started with a flow rate of 8 L/min [15, 21]. In the
study by Wing et al., children aged 0–18 years with
other conditions than bronchiolitis were included, with
flows varying from 8 to 50 L/min depending on the age
of the child [29]. A fourth study with intubation as out-
come used a flow rate of 2 L/kg/min, but did not include
a control group [32]. They reported that 12 % of infants
and children hospitalised to PICU for various respiratory
disorders supported on HFNC were in need of a step-up
treatment with CPAP or intubation. Another study
found no difference in intubation rate before and after
the initiation of HFNC in a general paediatric ward [36],
while in a further observational study, approximately
one-third of children commenced on HFNC in an emer-
gency department required escalation to a higher level
of respiratory support (CPAP or intubation) [35]. It is
also worth noting that although a recently published
RCT in adults found an overall decrease in mortality on
HFNC at a flow of 50 L/min compared to non-invasive
ventilation, there was no overall reduction in the intub-
ation rate when compared to standard oxygen or non-
invasive ventilation [47].
Role of high flow for other conditions than
bronchiolitis
A Cochrane analysis from 2014, studying the effect of
HFNC in children with other conditions than bron-
chiolitis, found no RCT and concluded that no evi-
dence was available to determine the safety or
effectiveness of HFNC as a form of respiratory sup-
port in children [7]. One small study has reported
less effect in children with respiratory distress due to
congenital heart disease than that with bronchiolitis
[30]. An association between heart disease and higher
failure rate of HFNC has also been observed [32].
However, in a recent published RCT studying HFNC
compared to conventional oxygen therapy during the
first 48 h after extubation for cardiac surgery, HFNC
improved PaO2, but not PaCO2 [28]. Clinical im-
provement by HFNC in children with obstructive
sleep apnoea has been found in two small studies [25,
53]. Case reports have also described an effect of
HFNC in children with acute pulmonary oedema [54]
and a paediatric burn patient with post extubation
stridor [55].
Side effects and safety
Most studies have reported no adverse events for chil-
dren on HFNC and have concluded that the use of
HFNC is safe both in a general paediatric ward [16, 20,
31], emergency department [14] and PICU [17, 27].
However, two reports described four serious cases of
pneumothorax in children on HFNC; one 2 month old
child treated for RSV bronchiolitis (flow rate 6–8 L/
min), one 16 year old child with cerebral palsy (flow rate
15–20 L/min), one 22 months old boy with a subdural
hematoma (flow rate 6 L/min) [48] and also in a 4 year
old child with asthma treated with HFNC (flow 40 L/
min) [35]. Unlike CPAP, which may be delivered by sys-
tems with an integrated pressure relief valve, it is not
possible to regulate or determine the pressure applied to
the airways in HFNC. In vitro and in vivo studies under-
line the risk of an HFNC device delivering high pres-
sures at higher flow rates, particularly if there is minimal
leak [42, 43, 45].
Three studies have reported abdominal distension in
children on HFNC, indicating that one should be careful
with HFNC in children with intra-abdominal pathology
[27, 28, 35]. Mucosal injury with nasal bleeding and ul-
ceration has been reported in children on HFNC [27],
but in a RCT including preterm infants below 32 weeks,
nasal trauma was less frequent in the HFNC group than
in the CPAP group [56].
An outbreak of Ralstonia mannitolilytica, a water-
borne opportunistic human pathogen, was found among
paediatric patients receiving HFNC in the US in 2005.
The outbreak was linked to intrinsic contamination of
the HFNC devices [57], but since changes to the device
no further infectious complications have been reported.
Conclusion
The majority of the studies on the use of HFNC beyond
the newborn period are small observational studies, with
a limited level of evidence of its use in infants and young
children. The results from the available studies suggest
that HFNC is a relatively safe, well-tolerated and feasible
method for delivering oxygen to infants and young chil-
dren in a general paediatric ward. Different mechanisms
including washout of nasopharyngeal dead space, in-
creased pulmonary compliance have been postulated,
but it is possible that some amount of distending airway
pressure may be the main reason for the effect.
Most of the clinical studies in children have been obser-
vational studies conducted in infants with bronchiolitis. A
positive clinical effect on various respiratory parameters has
been detected, and studies suggest that HFNC may reduce
the work of breathing. HFNC may also decrease the need
of CPAP and invasive ventilation in infants and children.
RCTs performed in preterm infants and adults suggest that
HFNC may be as effective as CPAP following extubation,
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while in children who have undergone cardiac surgery it
has been found to improve oxygenation in the post-
extubation period, when compared to low flow oxygen.
There are no international guidelines regarding flow
rates, and the varying flow rates used in the clinical studies
described in this paper, may explain the different results re-
garding effect. RCTs of HFNC including children beyond
the newborn period are currently ongoing [58]. Until more
evidence is available, HFNC may be used as a supplemen-
tary form of respiratory support in infants and children, but
with a critical approach regarding effective clinical re-
sponses and safety issues relating to early recognition of
treatment failure, particularly when children are managed
on HFNC outside of a paediatric intensive care unit.
Author’s contributions
IBM carried out the systematic literature search and drafted the manuscript.
PD participated in the interpretation of the results and the draft of the
manuscript. KØ participated in the design of the study, the interpretation of
the results and coordinated and helped to draft the manuscript. All authors
read and improved the final manuscript.
Competing interests
The authors have no competing interests.
Author details
1Department of Paediatrics, Stavanger University Hospital, P.O. Box 8100,
N-4068, Stavanger, Norway. 2Department of Clinical Science, University of
Bergen, Bergen, Norway. 3Department of Paediatric Intensive Care, Bristol
Royal Hospital for Children, Bristol, UK.
Received: 22 January 2016 Accepted: 17 June 2016
References
1. Klingenberg C, Pettersen M, Hansen EA, Gustavsen LJ, Dahl IA, Leknessund A,
et al. Patient comfort during treatment with heated humidified high flow nasal
cannulae versus nasal continuous positive airway pressure: a randomised
cross-over trial. Arch Dis Child Fetal Neonatal Ed. 2014;99:F134–7.
2. Roberts CT, Dawson JA, Alquoka E, Carew PJ, Donath SM, Davis PG, et al.
Are high flow nasal cannulae noisier than bubble CPAP for preterm infants?
Arch Dis Child Fetal Neonatal Ed. 2014;99:F291–5.
3. Roca O, Riera J, Torres F, Masclans JR. High-flow oxygen therapy in acute
respiratory failure. Respir Care. 2010;55:408–13.
4. Wilkinson D, Wilkinson D, Andersen C, O’Donnell CP, De Paoli AG. High flow
nasal cannula for respiratory support in preterm infants. Cochrane Database
Syst Rev. 2011;11(5):CD006405.
5. Dani C, Pratesi S, Migliori C, Bertini G. High flow nasal cannula therapy as
respiratory support in the preterm infant. Pediatr Pulmonol. 2009;44:629–34.
6. Myers TR. American Association for Respiratory C. AARC Clinical Practice
Guideline: selection of an oxygen delivery device for neonatal and pediatric
patients–2002 revision & update. Respir Care. 2002;47:707–16.
7. Mayfield S, Jauncey-Cooke J, Hough JL, Schibler A, Gibbons K, Bogossian F.
High-flow nasal cannula therapy for respiratory support in children.
Cochrane Database Syst Rev. 2014;3:CD009850.
8. Ojha S, Gridley E, Dorling J. Use of heated humidified high-flow nasal cannula
oxygen in neonates: a UK wide survey. Acta Paediatr. 2013;102:249–53.
9. Nishimura M. High-flow nasal cannula oxygen therapy in adults. J Intensive
Care. 2015;3:15.
10. Ward JJ. High-flow oxygen administration by nasal cannula for adult and
perinatal patients. Respir Care. 2013;58:98–122.
11. Manley BJ, Owen L, Doyle LW, Davis PG. High-flow nasal cannulae and nasal
continuous positive airway pressure use in non-tertiary special care nurseries in
Australia and New Zealand. J Paediatr Child Health. 2012;48:16–21.
12. Beggs S, Wong ZH, Kaul S, Ogden KJ, Walters JA. High-flow nasal cannula
therapy for infants with bronchiolitis. Cochrane Database Syst Rev. 2014;1:
CD009609.
13. Milesi C, Baleine J, Matecki S, Durand S, Combes C, Novais AR, et al. Is
treatment with a high flow nasal cannula effective in acute viral
bronchiolitis? A physiologic study. Intensive Care Med. 2013;39:1088–94.
14. Arora B, Mahajan P, Zidan MA, Sethuraman U. Nasopharyngeal airway
pressures in bronchiolitis patients treated with high-flow nasal cannula
oxygen therapy. Pediatr Emerg Care. 2012;28:1179–84.
15. Schibler A, Pham TM, Dunster KR, Foster K, Barlow A, Gibbons K, et al.
Reduced intubation rates for infants after introduction of high-flow
nasal prong oxygen delivery. Intensive Care Med. 2011;37:847–52.
16. Mayfield S, Bogossian F, O’Malley L, Schibler A. High-flow nasal cannula
oxygen therapy for infants with bronchiolitis: pilot study. J Paediatr Child
Health. 2014;50:373–8.
17. Hough JL, Pham TM, Schibler A. Physiologic effect of high-flow nasal
cannula in infants with bronchiolitis. Pediatr Crit Care Med. 2014;15:e214–9.
18. Bressan S, Balzani M, Krauss B, Pettenazzo A, Zanconato S, Baraldi E. High-
flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot
study. Eur J Pediatr. 2013;172:1649–56.
19. Abboud PA, Roth PJ, Skiles CL, Stolfi A, Rowin ME. Predictors of
failure in infants with viral bronchiolitis treated with high-flow, high-
humidity nasal cannula therapy*. Pediatr Crit Care Med.
2012;13:e343–9.
20. Bueno Campana M, Olivares Ortiz J, Notario Munoz C, Ruperez Lucas M,
Fernandez Rincon A, Patino Hernandez O, et al. High flow therapy versus
hypertonic saline in bronchiolitis: randomised controlled trial. Arch Dis
Child. 2014;99:511–5.
21. McKiernan C, Chua LC, Visintainer PF, Allen H. High flow nasal cannulae
therapy in infants with bronchiolitis. J Pediatr. 2010;156:634–8.
22. Metge P, Grimaldi C, Hassid S, Thomachot L, Loundou A, Martin C, et al.
Comparison of a high-flow humidified nasal cannula to nasal continuous
positive airway pressure in children with acute bronchiolitis: experience in a
pediatric intensive care unit. Eur J Pediatr. 2014;173:953–8.
23. Rubin S, Ghuman A, Deakers T, Khemani R, Ross P, Newth CJ. Effort of
breathing in children receiving high-flow nasal cannula. Pediatr Crit Care
Med. 2014;15:1–6.
24. Hilliard TN, Archer N, Laura H, Heraghty J, Cottis H, Mills K, et al. Pilot study
of vapotherm oxygen delivery in moderately severe bronchiolitis. Arch Dis
Child. 2012;97:182–3.
25. McGinley B, Halbower A, Schwartz AR, Smith PL, Patil SP, Schneider H. Effect
of a high-flow open nasal cannula system on obstructive sleep apnea in
children. Pediatrics. 2009;124:179–88.
26. Spentzas T, Minarik M, Patters AB, Vinson B, Stidham G. Children with
respiratory distress treated with high-flow nasal cannula. J Intensive Care
Med. 2009;24:323–8.
27. ten Brink F, Duke T, Evans J. High-flow nasal prong oxygen therapy or
nasopharyngeal continuous positive airway pressure for children with moderate-
to-severe respiratory distress?*. Pediatr Crit Care Med. 2013;14:e326–31.
28. Testa G, Iodice F, Ricci Z, Vitale V, De Razza F, Haiberger R, et al.
Comparative evaluation of high-flow nasal cannula and conventional
oxygen therapy in paediatric cardiac surgical patients: a randomized
controlled trial. Interact Cardiovasc Thorac Surg. 2014;19:456–61.
29. Wing R, James C, Maranda LS, Armsby CC. Use of high-flow nasal cannula
support in the emergency department reduces the need for intubation in
pediatric acute respiratory insufficiency. Pediatr Emerg Care. 2012;28:1117–23.
30. Pham TM, O’Malley L, Mayfield S, Martin S, Schibler A. The effect of high
flow nasal cannula therapy on the work of breathing in infants with
bronchiolitis. Pediatr Pulmonol. 2014;50:713–20.
31. Kallappa C, Hufton M, Millen G, Ninan TK. Use of high flow nasal
cannula oxygen (HFNCO) in infants with bronchiolitis on a paediatric
ward: a 3-year experience. Arch Dis Child. 2014;99:790–1.
32. Wraight TI, Ganu SS. High-flow nasal cannula use in a paediatric intensive
care unit over 3 years. Crit Care Resusc. 2015;17:197–201.
33. Milani GP, Plebani AM, Arturi E, Brusa D, Esposito S, Dell’Era L, et al.
Using a high-flow nasal cannula provided superior results to low-flow
oxygen delivery in moderate to severe bronchiolitis. Acta Paediatr.
2016. doi: 10.1111/apa.13444.
34. Kelly GS, Simon HK, Sturm JJ. High-flow nasal cannula use in children with
respiratory distress in the emergency department: predicting the need for
subsequent intubation. Pediatr Emerg Care. 2013;29:888–92.
35. Long E, Babl FE, Duke T. Is there a role for humidified heated high-flow
nasal cannula therapy in paediatric emergency departments? Emerg Med J.
2016;33:386–9.
Mikalsen et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2016) 24:93 Page 11 of 12
36. Riese J, Fierce J, Riese A, Alverson BK. Effect of a Hospital-wide High-Flow
Nasal Cannula Protocol on Clinical Outcomes and Resource Utilization of
Bronchiolitis Patients Admitted to the PICU. Hosp Pediatr. 2015;5:613–8.
37. Chisti MJ, Salam MA, Smith JH, Ahmed T, Pietroni MA, Shahunja KM, et al. Bubble
continuous positive airway pressure for children with severe pneumonia and
hypoxaemia in Bangladesh: an open, randomised controlled trial. Lancet. 2015;
386:1057–65.
38. Frizzola M, Miller TL, Rodriguez ME, Zhu Y, Rojas J, Hesek A, et al. High-flow
nasal cannula: impact on oxygenation and ventilation in an acute lung
injury model. Pediatr Pulmonol. 2011;46:67–74.
39. Dysart K, Miller TL, Wolfson MR, Shaffer TH. Research in high flow therapy:
mechanisms of action. Respir Med. 2009;103:1400–5.
40. Chidekel A, Zhu Y, Wang J, Mosko JJ, Rodriguez E, Shaffer TH. The
effects of gas humidification with high-flow nasal cannula on
cultured human airway epithelial cells. Pulm Med. 2012;2012:380686.
41. Braunlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H. Effects of
nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary
fibrosis patients. Respiration. 2013;85:319–25.
42. Locke RG, Wolfson MR, Shaffer TH, Rubenstein SD, Greenspan JS. Inadvertent
administration of positive end-distending pressure during nasal cannula flow.
Pediatrics. 1993;91:135–8.
43. Hasan RA, Habib RH. Effects of flow rate and airleak at the nares and mouth
opening on positive distending pressure delivery using commercially
available high-flow nasal cannula systems: a lung model study. Pediatr Crit
Care Med. 2011;12:e29–33.
44. Kubicka ZJ, Limauro J, Darnall RA. Heated, humidified high-flow nasal cannula
therapy: yet another way to deliver continuous positive airway pressure?
Pediatrics. 2008;121:82–8.
45. Sivieri EM, Gerdes JS, Abbasi S. Effect of HFNC flow rate, cannula size, and
nares diameter on generated airway pressures: an in vitro study. Pediatr
Pulmonol. 2013;48:506–14.
46. Hutchings FA, Hilliard TN, Davis PJ. Heated humidified high-flow nasal
cannula therapy in children. Arch Dis Child. 2015;100:571–5.
47. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow
oxygen through nasal cannula in acute hypoxemic respiratory failure.
N Engl J Med. 2015;372:2185–96.
48. Hegde S, Prodhan P. Serious air leak syndrome complicating high-flow nasal
cannula therapy: a report of 3 cases. Pediatrics. 2013;131:e939–44.
49. Lampland AL, Plumm B, Meyers PA, Worwa CT, Mammel MC. Observational
study of humidified high-flow nasal cannula compared with nasal
continuous positive airway pressure. J Pediatr. 2009;154:177–82.
50. Collins CL, Holberton JR, Barfield C, Davis PG. A randomized controlled trial
to compare heated humidified high-flow nasal cannulae with nasal
continuous positive airway pressure postextubation in premature infants.
J Pediatr. 2013;162:949–54 e1.
51. Manley BJ, Owen LS, Doyle LW, Andersen CC, Cartwright DW, Pritchard MA,
et al. High-flow nasal cannulae in very preterm infants after extubation.
N Engl J Med. 2013;369:1425–33.
52. Yoder BA, Stoddard RA, Li M, King J, Dirnberger DR, Abbasi S. Heated,
humidified high-flow nasal cannula versus nasal CPAP for respiratory
support in neonates. Pediatrics. 2013;131:e1482–90.
53. Joseph L, Goldberg S, Shitrit M, Picard E. High-Flow Nasal Cannula Therapy
for Obstructive Sleep Apnea in Children. J Clin Sleep Med. 2015;11:1007–10.
54. Kumar J, Hegde R, Maheshwari S, Rao S. Flash pulmonary edema in a
post arterial switch operation - High flow oxygen as a treatment
modality. Ann Pediatr Cardiol. 2009;2:175–6.
55. Byerly FL, Haithcock JA, Buchanan IB, Short KA, Cairns BA. Use of high flow
nasal cannula on a pediatric burn patient with inhalation injury and post-
extubation stridor. Burns. 2006;32:121–5.
56. Collins CL, Barfield C, Horne RS, Davis PG. A comparison of nasal trauma in
preterm infants extubated to either heated humidified high-flow nasal cannulae
or nasal continuous positive airway pressure. Eur J Pediatr. 2014;173:181–6.
57. Jhung MA, Sunenshine RH, Noble-Wang J, Coffin SE, St John K, Lewis FM,
et al. A national outbreak of Ralstonia mannitolilytica associated with use of
a contaminated oxygen-delivery device among pediatric patients. Pediatrics.
2007;119:1061–8.
58. Franklin D, Dalziel S, Schlapbach LJ, Babl FE, Oakley E, Craig SS, et al. Early
high flow nasal cannula therapy in bronchiolitis, a prospective randomised
control trial (protocol): A Paediatric Acute Respiratory Intervention Study
(PARIS). BMC Pediatr. 2015;15:183.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mikalsen et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2016) 24:93 Page 12 of 12
